替尔泊肽对比德谷胰岛素对2型糖尿病患者肝脏脂肪含量及腹部脂肪组织的影响(SURPASS-3 MRI):随机、开放标签、平行组、3期SURPASS-3试验的子研究
该子研究在8个国家45个中心纳入296例2型糖尿病患者,随机接受替尔泊肽5、10、15 mg或德谷胰岛素治疗52周。替尔泊肽10 mg与15 mg合并组肝脏脂肪含量绝对降幅为-8.09%,德谷胰岛素组为-3.38%,估计治疗差异为-4.71%(95%CI -6.72至-2.70;p<0.0001)。替尔泊肽组肝脏脂肪含量降幅与基线肝脏脂肪含量、内脏脂肪组织、腹部皮下脂肪组织及体重下降显著相关。
要点
- 替尔泊肽10 mg与15 mg合并组52周肝脏脂肪含量降幅显著大于德谷胰岛素组。
- 估计治疗差异为-4.71%(95%CI -6.72至-2.70;p<0.0001)。
- 替尔泊肽组肝脏脂肪含量降幅与基线肝脏脂肪含量、内脏脂肪、腹部皮下脂肪及体重下降显著相关。
核心结论
- 在SURPASS-3研究的2型糖尿病亚组人群中,替尔泊肽较德谷胰岛素显著降低肝脏脂肪含量以及内脏脂肪组织和腹部皮下脂肪组织体积。
研究设计与样本
- 本子研究为随机、开放标签、平行组、3期SURPASS-3试验的子研究,在8个国家45个医学研究中心和医院进行。
- 纳入标准为成人2型糖尿病、基线HbA1c 7.0-10.5%(53-91 mmol/mol)、BMI至少25 kg/m2、体重稳定、未使用过胰岛素、筛查前至少3个月单用二甲双胍或联合SGLT2抑制剂治疗,且子研究参与者还需肝脏脂肪指数至少60。
- 参与者按1:1:1:1随机分配至每周一次皮下注射替尔泊肽5 mg、10 mg或15 mg,或每日一次皮下注射滴定德谷胰岛素,按国家、HbA1c和合并口服降糖药分层。
- 主要疗效终点为第52周肝脏脂肪含量(以MRI质子密度脂肪分数[MRI-PDFF]测量)较基线的变化,比较替尔泊肽10 mg与15 mg组合并数据 versus 德谷胰岛素。
- 分析在入组MRI人群中进行,该人群为主研究改良意向治疗人群中基线或基线后具有有效MRI的参与者。
主要发现
- 2019年4月1日至2019年11月15日,502例参与者接受子研究资格评估,其中296例(59%)纳入入组MRI人群并随机分配治疗(替尔泊肽5 mg组n=71;替尔泊肽10 mg组n=79;替尔泊肽15 mg组n=72;德谷胰岛素组n=74)。
- 从总体平均基线肝脏脂肪含量15.71%(SD 8.93)起,第52周替尔泊肽10 mg与15 mg合并组肝脏脂肪含量绝对降幅为-8.09%(SE 0.57),德谷胰岛素组为-3.38%(SE 0.83)。
- 替尔泊肽10 mg与15 mg合并组 versus 德谷胰岛素的估计治疗差异为-4.71%(95%CI -6.72至-2.70;p<0.0001)。
- 在替尔泊肽组中,肝脏脂肪含量降幅与基线肝脏脂肪含量(ρ=-0.71)、内脏脂肪组织降幅(ρ=0.29)、腹部皮下脂肪组织降幅(ρ=0.33)及体重降幅(ρ=0.34)显著相关(p≤0.0006)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 diabetes. The aim of this substudy was to characterise the changes in liver fat content (LFC), volume of visceral adipose tissue (VAT), and abdominal subcutaneous adipose tissue (ASAT) in response to tirzepatide or insulin degludec in a subpopulation of the SURPASS-3 study. METHODS: This substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial was done at 45 medical research centres and hospitals across eight countries (Argentina, Austria, Greece, Hungary, Italy, Romania, Spain, and the USA). Eligible participants were adults with type 2 diabetes, a baseline HbA1c 7·0-10·5% (53-91 mmol/mol), a BMI of at least 25 kg/m2, stable weight, were insulin-naive, and on treatment with metformin alone or in combination with a SGLT2 inhibitor for at least 3 months before screening. In addition to the main study inclusion criteria, substudy participants had a fatty liver index of at least 60. Participants had an MRI scan and were randomised (1:1:1:1) in the main study to subcutaneous injection once per week of tirzepatide 5 mg, 10 mg, or 15 mg, or subcutaneous injection once per day of titrated insulin degludec, using an interactive web-response system, and were stratified by country, HbA1c, and concomitant oral anti-hyperglycaemic medication. The primary efficacy endpoint was the change from baseline in LFC (as measured by MRI-proton density fat fraction [MRI-PDFF]) at week 52 using pooled data from the tirzepatide 10 mg and 15 mg groups versus insulin degludec. Analyses were assessed in the enrolled MRI population, which consisted of participants in the modified intention-to-treat population of the main study who also had a valid MRI at either baseline or after baseline. This is a substudy of the trial registered with ClinicalTrials.gov, number NCT03882970, and is complete. FINDINGS: From April 1, 2019, to Nov 15, 2019, 502 participants were assessed for eligibility to participate in this substudy, 296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74). Baseline demographics and clinical characteristics were similar across all treatment groups. From an overall mean baseline LFC of 15·71% (SD 8·93), the absolute reduction in LFC at week 52 was significantly greater for the pooled tirzepatide 10 mg and 15 mg groups (-8·09%, SE 0·57) versus the insulin degludec group (-3·38%, 0·83). The estimated treatment difference versus insulin degludec was -4·71% (95% CI -6·72 to -2·70; p<0·0001). The reduction in LFC was significantly correlated (p≤0·0006) with baseline LFC (ρ=-0·71), reductions in VAT (ρ=0·29), reductions in ASAT (ρ=0·33), and reductions in body weight (ρ=0·34) in the tirzepatide groups. INTERPRETATION: Tirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study. These data provide additional evidence on the metabolic effects of this novel dual GIP and GLP-1 receptor agonist. FUNDING: Eli Lilly and Company.
引用
- Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022. PMID: 35468325. doi:10.1016/S2213-8587(22)00070-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。